Source 1primary paper2025MED
Toolkit/ARA-LNP
ARA-LNP
Also known as: bioactive nanocarrier, novel LNP integrating arachidonic acid
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
We designed and synthesized a novel LNP by integrating the pro-inflammatory fatty acid, arachidonic acid (ARA), as a functional structural component (ARA-LNP).
Usefulness & Problems
No literature-backed usefulness or problem-fit explainer has been materialized for this record yet.
Published Workflows
Objective: Develop a bioactive lipid nanoparticle that improves mRNA delivery into primary macrophages and use it to generate functional HER2-targeting CAR-macrophages.
Why it works: The paper hypothesizes that embedding a cellular modulator within the LNP structure can synergistically overcome biological barriers in primary macrophages that are not solved by physicochemical optimization alone.
transient modulation of target cell state by the nanocarrierintegration of arachidonic acid as a functional structural componentLNP design and synthesisformulation optimizationmRNA deliveryin vitro functional phagocytosis testing
Stages
- 1.ARA-LNP design and synthesis(library_build)
To instantiate the proposed bioactive nanocarrier paradigm before optimization and testing.
Selection: Create a novel LNP incorporating arachidonic acid as a functional structural component.
- 2.Formulation optimization in primary macrophages(broad_screen)
To identify a formulation that overcomes macrophage transfection barriers before applying the platform to CAR-M generation.
Selection: Optimize ARA content and mRNA payload for transfection efficiency in primary M2-polarized BMDMs.
- 3.Functional CAR-macrophage validation(confirmatory_validation)
To confirm that improved delivery translates into a therapeutically relevant macrophage engineering outcome.
Selection: Use the optimized delivery platform to generate HER2-targeting CAR-M and test phagocytic function against HER2-expressing tumor cells.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Target processes
No target processes tagged yet.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
successPrimary Cellsapplication demomouseM2-polarized bone marrow-derived macrophages
Inferred from claim c2 during normalization. An optimized ARA-LNP formulation achieved 83.76% transfection efficiency in primary M2-polarized bone marrow-derived macrophages. Derived from claim c2. Quoted text: Systematic optimization of the ARA content and mRNA payload revealed a formulation that achieves high transfection efficiency (83.76%) in primary M2-polarized bone marrow-derived macrophages (BMDMs)
Source:
transfection efficiency83.76 %
successPrimary Cellsapplication demo
in vitro phagocytosis assay
Inferred from claim c3 during normalization. Using the ARA-LNP delivery platform, the authors generated HER2-targeting CAR-macrophages with potent and specific phagocytic activity against HER2-expressing tumor cells in vitro. Derived from claim c3. Quoted text: Leveraging this advanced delivery platform, we successfully generated HER2-targeting CAR-M that demonstrated potent and specific phagocytic activity against HER2-expressing tumor cells in vitro.
Source:
Supporting Sources
Ranked Claims
Using the ARA-LNP delivery platform, the authors generated HER2-targeting CAR-macrophages with potent and specific phagocytic activity against HER2-expressing tumor cells in vitro.
Leveraging this advanced delivery platform, we successfully generated HER2-targeting CAR-M that demonstrated potent and specific phagocytic activity against HER2-expressing tumor cells in vitro.
Incorporating a cellular modulator directly into LNP structure is proposed to synergistically overcome intrinsic biological barriers to gene delivery in primary macrophages.
Here, we introduced a "bioactive nanocarrier" paradigm, hypothesizing that incorporating a cellular modulator directly into LNP structure can synergistically overcome these barriers.
The study presents a design principle in which the nanocarrier transiently modulates target cell state to enhance gene delivery for macrophages and other hard-to-transfect immune cells.
This work presents a powerful strategy where the nanocarrier itself transiently modulates the target cell state to enhance gene delivery, providing a new design principle for engineering macrophages and other hard-to-transfect immune cells for therapeutic applications.
An optimized ARA-LNP formulation achieved 83.76% transfection efficiency in primary M2-polarized bone marrow-derived macrophages.
Systematic optimization of the ARA content and mRNA payload revealed a formulation that achieves high transfection efficiency (83.76%) in primary M2-polarized bone marrow-derived macrophages (BMDMs)
transfection efficiency 83.76 %
Approval Evidence
1 source4 linked approval claimsfirst-pass slug ara-lnp
We designed and synthesized a novel LNP by integrating the pro-inflammatory fatty acid, arachidonic acid (ARA), as a functional structural component (ARA-LNP).
Source:
applicationsupports
Using the ARA-LNP delivery platform, the authors generated HER2-targeting CAR-macrophages with potent and specific phagocytic activity against HER2-expressing tumor cells in vitro.
Leveraging this advanced delivery platform, we successfully generated HER2-targeting CAR-M that demonstrated potent and specific phagocytic activity against HER2-expressing tumor cells in vitro.
Source:
design rationalesupports
Incorporating a cellular modulator directly into LNP structure is proposed to synergistically overcome intrinsic biological barriers to gene delivery in primary macrophages.
Here, we introduced a "bioactive nanocarrier" paradigm, hypothesizing that incorporating a cellular modulator directly into LNP structure can synergistically overcome these barriers.
Source:
generalizationsupports
The study presents a design principle in which the nanocarrier transiently modulates target cell state to enhance gene delivery for macrophages and other hard-to-transfect immune cells.
This work presents a powerful strategy where the nanocarrier itself transiently modulates the target cell state to enhance gene delivery, providing a new design principle for engineering macrophages and other hard-to-transfect immune cells for therapeutic applications.
Source:
performancesupports
An optimized ARA-LNP formulation achieved 83.76% transfection efficiency in primary M2-polarized bone marrow-derived macrophages.
Systematic optimization of the ARA content and mRNA payload revealed a formulation that achieves high transfection efficiency (83.76%) in primary M2-polarized bone marrow-derived macrophages (BMDMs)
Source:
Comparisons
No literature-backed comparison notes have been materialized for this record yet.
Ranked Citations
- 1.